The CDC's vaccine advisory committee is set to meet for the first time since HHS Secretary Robert F. Kennedy Jr. dismissed ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

This resource details recent developments in vaccinations, how addressing misinformation and hesitancy can improve public health, updated vaccination guidelines and more.

Dr Fiona Havers resigned from her role tracking viral epidemics for the CDC due to a lack of confidence in the current leadership.

Newer formulations are even more effective at preventing illnesses that commonly afflict seniors — perhaps even dementia.

The fifth Symposium on Infectious Disease in the Immunocompromised Host convened in Seattle last month. Experts and rising ...

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.